Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease. METHODS: A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews. RESULTS: Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [+/-SD] age at onset, 60.0+/-14.2 years vs. 64.2+/-11.7 years; P=0.04). CONCLUSIONS: Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is a center for cellular signaling and signal integration, has responsibilities in trafficking cargo, and functionally interacts with other organelles.1,9”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Aharon-Peretz et al. 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Research works printed but not linked: 1
- 10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j · doi:10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j
Cited by
Items 101–200 of 608
Gaucher Disease: Clinical, Biological and Therapeutic Aspects
Dandana, A., Khelifa, S. B., Chahed, H., Miled, A., & Ferchichi, S. (2015) · Pathobiology · doi:10.1159/000440865 · Cited by 146
Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia
Fratta, P., Poulter, M., Lashley, T., Rohrer, J. D., Polke, J. M., Beck, J., Ryan, N., Hensman, D., Mizielinska, S., Waite, A. J., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1147-0 · Cited by 137
“Examples include heterozygous LOF mutations in the progranulin gene (PGRN) causing FTD but homozygous mutations causing a lysosomal storage disorder [4, 29]; mutations in GBA causing Parkinson’s disease in heterozygosity and Gaucher’s disease in homozygosity [1]; and mutations in TREM2 causing Alzheimer’s disease and…”
BackgroundLin, K.-J., Lin, K.-L., Chen, S.-D., Liou, C.-W., Chuang, Y.-C., Lin, H.-Y., & Lin, T.-K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215312 · Cited by 139
Increased incidence of Parkinson disease among relatives of patients with Gaucher disease
Halperin, A., Elstein, D., & Zimran, A. (2006) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2006.02.004 · Cited by 138
The role of monogenic genes in idiopathic Parkinson’s disease
Reed, X., Bandrés-Ciga, S., Blauwendraat, C., & Cookson, M. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.012 · Cited by 129
“Clinically, Gaucher disease patients can display parkinsonian symptoms, and many studies have identified an increased frequency of heterozygous GBA mutations in PD cohorts (Aharon-Peretz et al., 2004; Clark et al., 2007).”
BackgroundRole of the endolysosomal system in Parkinson’s disease
Vidyadhara, D. J., Lee, J. E., & Chandra, S. S. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14820 · Cited by 136
Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study
Malek, N., Weil, R. S., Bresner, C., Lawton, M. A., Grosset, K. A., Tan, M., Bajaj, N., Barker, R. A., Burn, D. J., Foltynie, T., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317348 · Cited by 133
Bras, J., Singleton, A., Cookson, M. R., & Hardy, J. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06709.x · Cited by 132
“GBA mutations, in addition to causing Gaucher disease when homozygous, have recently been established to act as a risk factor for PD [13,14] and for Lewy body disorders [15].”
Dumitriu, A., Golji, J., Labadorf, A. T., Gao, B., Beach, T. G., Myers, R. H., Longo, K. A., & Latourelle, J. C. (2015) · BMC Medical Genomics · doi:10.1186/s12920-016-0164-y · Cited by 133
“Familial monogenic forms of PD have been identified, with the most common of these attributed to mutations in the leucine-rich repeat kinase 2 (LRRK2) [2], Parkin (PARK2) [3] and Glucosidase, Beta, Acid (GBA) [4] genes, and with several rare monogenic forms recognized, including rare mutations in the alphasynuclein ge…”
BackgroundParkinson's disease: convergence on synaptic homeostasis
Soukup, S., Vanhauwaert, R., & Verstreken, P. (2018) · The EMBO Journal · doi:10.15252/embj.201898960 · Cited by 130
“ATP13A2 and glucocerebrosidase regulate lysosomal function and autosomal-recessive mutations in ATP13A2 cause PD, while heterozygosity for GBA predisposes to PD (Aharon-Peretz et al, 2004).”
BackgroundWolf, J., Rasmussen, D. K., Sun, Y. J., Vu, J. T., Wang, E., Espinosa, C. A., Bigini, F., Chang, R. T., Montague, A. A., Tang, P. H., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.012 · Cited by 136
Inborn errors of metabolism: the flux from Mendelian to complex diseases
Lanpher, B. C., Brunetti‐Pierri, N., & Lee, B. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1880 · Cited by 148
Pankratz, N., & Foroud, T. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e31815bf97c · Cited by 158
Lysosomal adaptation: how the lysosome responds to external cues
Settembre, C., & Ballabio, A. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016907 · Cited by 126
“Of particular interest is the finding of mutations in the gene encoding the lysosomal enzyme b-glucocerebrosidase in a significant number of patients with Parkinson’s disease, particularly among Ashkenazi Jews (Aharon-Peretz et al. 2004; Shachar et al. 2011).”
BackgroundEtiology and Pathogenesis of Parkinson Disease
Schapira, A. H. V. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.004 · Cited by 150
Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation
Fishbein, I., Kuo, Y.-M., Giasson, B. I., & Nussbaum, R. L. (2014) · Brain · doi:10.1093/brain/awu291 · Cited by 116
“These were followed by an association study done in an Ashkenazi Jewish population, indicating that even heterozygosity for Gaucher disease mutations may predispose their carriers to Parkinson’s disease (Aharon-Peretz et al., 2004).”
Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation
Zheng, Y.-Q., Zhang, Y., Yau, Y., Zeighami, Y., Larcher, K., Misic, B., & Dagher, A. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000495 · Cited by 125
“Mutations in GBA are the most common genetic risk factor for PD [55, 56]; mutations and multiplications of SNCA have been implicated in driving the severity of the pathology [57–59].”
BackgroundAge-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling
Rana, H. Q., Balwani, M., Bier, L., & Alcalay, R. N. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.107 · Cited by 118
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal
Brás, J., Paisán‐Ruiz, C., Guerreiro, R. J., Ribeiro, M. H., Morgadinho, A., Januário, C., Sidransky, E., Oliveira, C. R., & Singleton, A. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.016 · Cited by 117
Epidemiology and natural history of Gaucher's disease
Mehta, A. B. (2006) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2006.07.005 · Cited by 117
“If more evidence is required on the way in which complex organs are disturbed, the association of Gaucher's disease with Parkinson's disease has recently been emphasized in a study from the New England Journal of Medicine [3].”
BackgroundParkinson’s disease: experimental models and reality
Jiang, P., & Dickson, D. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1788-5 · Cited by 111
“Support for this hypothesis is the mounting evidence of changes in autophagic vacuoles or autophagy-related markers in postmortem PD brains [5, 43, 212], as well as discoveries of autophagy-lysosomal related genetic abnormalities in familial PD [1, 163, 180].”
Ginns, E. I., Mak, S. K., Ko, N., Karlgren, J., Akbarian, S., Chou, V., Guo, Y., Lim, A., Samuelsson, S. J., LaMarca, M. L., et al. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.12.003 · Cited by 123
Unfolded protein response in Gaucher disease: from human to Drosophila
Maor, G., Rencus‐Lazar, S., Filocamo, M., Steller, H., Segal, D., & Horowitz, M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-140 · Cited by 119
“Thus, GD patients and carriers of GD mutations are prone to develop PD [31-55].”
BackgroundImpact of recent genetic findings in Parkinson??s disease
Klein, C., & Lohmann-Hedrich, K. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3281e6692b · Cited by 141
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease
Beavan, M. S., & Schapira, A. H. V. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.849003 · Cited by 107
SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease
Alcalay, R. N., Mallett, V., Vanderperre, B., Tavassoly, O., Dauvilliers, Y., Wu, R. Y. J., Ruskey, J. A., Leblond, C. S., Ambalavanan, A., Laurent, S. B., et al. (2019) · Movement Disorders · doi:10.1002/mds.27642 · Cited by 110
“For example, when the association of GBA with PD was initially described, there were conflicting results because of 1 study combining all mutations with a positive association and another report on negative association in which the separate effect of only 1 mutation was examined.(26,27) Subsequent studies that include…”
ResultLRRK2 and the Endolysosomal System in Parkinson’s Disease
Erb, M. L., & Moore, D. J. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202138 · Cited by 121
Gaucher Disease and Its Treatment Options
Bennett, L. L., & Mohan, D. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013500469 · Cited by 109
Variants in GBA , SNCA , and MAPT influence Parkinson disease risk, age at onset, and progression
Davis, A. A., Andruska, K. M., Benítez, B. A., Racette, B. A., Perlmutter, J. S., & Cruchaga, C. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.014 · Cited by 119
“Previous studies in multiple genetically diverse cohorts of PD patients have found associations between age at onset (AAO) of PD and SNPs in multiple genes including GBA, SNCA, MAPT, and COMT [15, 17-22].”
BackgroundResultInfluentialGlucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease
Ziegler, S. G., Eblan, M. J., Gutti, U., Hruska, K. S., Stubblefield, B. K., Göker-Alpan, Ö., LaMarca, M. E., & Sidransky, E. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.03.004 · Cited by 115
“However, a subsequent study in a cohort of 99 Ashkenazi Jewish probands with PD from Northern Israel demonstrated that as many as 31% of subjects carried one of six specific GBA mutations, which was fivefold higher than found in the ethnically matched general population controls [18].”
BackgroundResultMitra, S., Anjum, J., Muni, M., Das, R. C., Rauf, A., Islam, F., Emran, T. B., Semwal, P., Hemeg, H. A., Alhumaydhi, F. A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112877 · Cited by 107
Molecular Chaperones as Rational Drug Targets for Parkinsons Disease Therapeutics
Kalia, S. K., Kalia, L. V., & McLean, P. J. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710793237386 · Cited by 108
“More recently, heterozygous mutations in the 3-glucocerebrosidase (GBA) gene, which encodes the lysosomal enzyme affected in Gaucher disease, have been identified as susceptibility factors for idiopathic PD [11].”
BackgroundPapadopoulos, V. E., Nikolopoulou, G., Antoniadou, I., Karachaliou, A., Arianoglou, G., Emmanouilidou, E., Sardi, S. P., Stefanis, L., & Vekrellis, K. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy075 · Cited by 95
Ethnicity-Related Polymorphisms and Haplotypes in the Human ABCB1 Gene
Kimchi‐Sarfaty, C., Marple, A., Shinar, S., Kimchi, A. M., Scavo, D., Roma, M. I., Kim, I., Jones, A., Arora, M., Gribar, J. J., et al. (2006) · Pharmacogenomics · doi:10.2217/14622416.8.1.29 · Cited by 118
“breast and ovarian cancers [20], Gaucher’s and Parkinson’s diseases [21], and Crohn’s disease [22].”
BackgroundRon, I., Rapaport, D., & Horowitz, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq292 · Cited by 97
“The N370S mutation is a mild mutation, most prevalent among Ashkenazi Jews (49,50), which was found in association with PD (20,21,26,51).”
BackgroundResultYahalom, G., Greenbaum, L., Israeli‐Korn, S., Fay‐Karmon, T., Livneh, V., Ruskey, J. A., Roncière, L., Alam, A., Gan‐Or, Z., & Hassin‐Baer, S. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.12.014 · Cited by 99
“G2019S mutation in the leucinerich repeat kinase 2 (LRRK2) gene and several variations in the glucocerebrosidase (GBA) gene are frequent among AJ patients [3,4].”
BackgroundGlucocerebrosidase gene mutations and Parkinson disease in the Norwegian population
Toft, M., Pielsticker, L. K., Ross, O. A., Aasly, J. O., & Farrer, M. J. (2006) · Neurology · doi:10.1212/01.wnl.0000196492.80676.7c · Cited by 98
Lin, C., Chen, P., Tai, C., Lin, H., Chen, C., Chen, M., & Wu, R. (2019) · Movement Disorders · doi:10.1002/mds.27633 · Cited by 101
“L444P mutations.(31) Seventeen of the 138 probands with an AD inheritance pattern of parkinsonism (12.”
BackgroundUncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic
Lim, S., Tan, A. H., Ahmad‐Annuar, A., Okubadejo, N. U., Lohmann, K., Morris, H. R., Toh, T. S., Tay, Y. W., Lange, L. M., Bandrés‐Ciga, S., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00378-8 · Cited by 101
The Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Eblan, M. J., Walker, J. M., & Sidransky, E. (2005) · New England Journal of Medicine · doi:10.1056/nejm200502173520719 · Cited by 96
Wang, C., Cai, Y., Gu, Z., Ma, J., Zheng, Z., Tang, B., Xu, Y., Zhou, Y., Feng, T., Wang, T., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.012 · Cited by 98
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Sjödin, S., Brinkmalm, G., Öhrfelt, A., Parnetti, L., Paciotti, S., Hansson, O., Hardy, J., Blennow, K., Zetterberg, H., & Brinkmalm, A. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0533-9 · Cited by 90
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece
Kalinderi, K., Bostantjopoulou, S., Paisán‐Ruiz, C., Katsarou, Z., Hardy, J., & Fidani, L. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.029 · Cited by 94
“2004) led others to assess Jewish and non-Jewish populations (Aharon-Peretz et al. 2004; Ziegler et al. 2007).”
Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson’s Disease
Monfrini, E., & Fonzo, A. D. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-49969-7_1 · Cited by 98
Behl, T., Kaur, G., Frățilă, O., Buhaș, C. L., Pusta, C. T. J., Negruţ, N., Bustea, C., & BUNGAU, S. G. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-020-00226-x · Cited by 98
Genes associated with Parkinson syndrome
Biskup, S., Gerlach, M., Kupsch, A. R., Reichmann, H., Riederer, P. F., Vieregge, P., Wüllner, U., & Gasser, T. (2008) · Journal of Neurology · doi:10.1007/s00415-008-5005-2 · Cited by 105
“Screening of PS patients for GBA mutations found a higher number of heterozygous mutations carriers as compared to healthy controls [2].”
BackgroundWu, Y.-R., Chen, C.-M., Chao, C.-Y., Ro, L.-S., Lyu, R.-K., Chang, K.-H., & Lee-Chen, G.-J. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.105940 · Cited by 89
Life expectancy in Gaucher disease type 1
Weinreb, N. J., Deegan, P. B., Kacena, K. A., Mistry, P. K., Pastores, G. M., Velentgas, P., & Dahl, S. V. (2008) · American Journal of Hematology · doi:10.1002/ajh.21305 · Cited by 90
“Additionally, unanticipated findings such as the inordinately high proportion of even heterozygous Gaucher (GBA) mutations found worldwide among patients with Parkinson's disease [8,9] suggest the need for further examination of factors that may influence outcomes including life expectancy in patients with GD1.”
BackgroundNosology of Parkinson’s Disease: Looking for the Way Out of a Quackmire
Forman, M. S., Lee, V. M. ‐., & Trojanowski, J. Q. (2005) · Neuron · doi:10.1016/j.neuron.2005.07.021 · Cited by 108
“In contrast, heterozygous mutations were recently identified in the GBA (glucocerebrosidase) gene as a significant genetic risk factor for the development of otherwise typical Lewy body PD in Ashkenazi Jews (Aharon-Peretz et al., 2004).”
BackgroundLimelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration
Wales, P., Pinho, R., Lázaro, D. F., & Outeiro, T. F. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130216 · Cited by 86
Courage, C., Oliver, K. L., Park, E. J., Cameron, J. M., Grabińska, K. A., Muona, M., Canafoglia, L., Gambardella, A., Said, E., Afawi, Z., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.03.013 · Cited by 88
Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death
Bourdenx, M., Bezard, E., & Dehay, B. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00083 · Cited by 81
“, 2006) and the enzyme glucocerebrosidase (GBA; Aharon-Peretz et al., 2004; Di Fonzo et al., 2007; Sidransky et al., 2009).”
BackgroundA rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson's disease
Foo, J. N., Liany, H., Bei, J., Yu, X.-Q., Liu, J., Au, W., Prakash, K. M., Tan, L., & Tan, E.-K. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.010 · Cited by 88
“Carriers of mutations in GBA causing Gaucher’s disease, the most common lysosomal storage disorder, are at significantly increased risk for developing PD, with an earlier age of onset compared with PD patients who do not carry these mutations (Aharon-Peretz et al., 2004).”
BackgroundBiegstraaten, M., van Schaik, I. N., Aerts, J. M. F. G., & Hollak, C. E. M. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0832-y · Cited by 94
“…Gaucher disease and parkinsonism, leading to an increased incidence not only in patients but also in carriers of a glucocerebrosidase mutation (Aharon-Peretz et al 2004, 2005; Bembi et al 2003; Clark et al 2005; Cormand et al 1995, 1998; Eblan et al 2006a, b; Goker-Alpan et al 2004; Halperin…”
Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization
Saunders‐Pullman, R., Hagenah, J., Dhawan, V., Stanley, K., Pastores, G., Sathe, S., Tagliati, M., Condefer, K., Palmese, C., Brüggemann, N., et al. (2010) · Movement Disorders · doi:10.1002/mds.23046 · Cited by 86
“Most reported cases of PD associated with GD are ascertained because of systemic features, such as anemia or bone changes; only a few cases of GBA homozygotes or compound heterozygotes, asymptomatic for other features of GD, have been identified in a PD clinic setting.(2,14) Further, neuroimaging, and formal neuropsyc…”
BackgroundGenetics of Parkinson's Disease
Koros, C., Simitsi, A., & Stefanis, L. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.01.009 · Cited by 97
Progress in the pathogenesis and genetics of Parkinson's disease
Mizuno, Y., Hattori, N., Kubo, S., Sato, S., Nishioka, K., Hatano, T., Tomiyama, H., Funayama, M., Machida, Y., & Mochizuki, H. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.2273 · Cited by 107
Zhang, Y., Li, S., Sun, Q., Zhou, X. C., Pan, H., Guo, J., & Tang, B. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00043 · Cited by 89
Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression
Ortega, R. A., Wang, C., Raymond, D., Bryant, N., Scherzer, C. R., Thaler, A., Alcalay, R. N., West, A. B., Mirelman, A., Kuras, Y. I., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.5845 · Cited by 89
Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment
Siderowf, A. D., & Stern, M. B. (2009) · Annals of Neurology · doi:10.1002/ana.21462 · Cited by 96
Towards a complete resolution of the genetic architecture of disease
Singleton, A. B., Hardy, J., Traynor, B. J., & Houlden, H. (2010) · Trends in Genetics · doi:10.1016/j.tig.2010.07.004 · Cited by 86
Molecular pathogenesis of Parkinson's disease: update
Saiki, S., Sato, S., & Hattori, N. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301205 · Cited by 105
Clinical manifestations and management of Gaucher disease
Linari, S. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.157 · Cited by 85
“Recently, a clinical association has been reported between the presence of mutations in the β-glucocerebrosidase gene and Parkinsonism (22, 23).”
BackgroundClinicogenetic study of GBA mutations in patients with familial Parkinson's disease
Li, Y., Sekine, T., Funayama, M., Li, L., Yoshino, H., Nishioka, K., Tomiyama, H., & Hattori, N. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.019 · Cited by 91
Conrad, K. S., Cheng, T.-W., Ysselstein, D., Heybrock, S., Hoth, L. R., Chrunyk, B. A., am Ende, C. W., Krainc, D., Schwake, M., Saftig, P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02044-8 · Cited by 80
Effect of Trehalose on PC12 Cells Overexpressing Wild-Type or A53T Mutant α-synuclein
Lan, D.-M., Liu, F., Zhao, J., Chen, Y., Wu, J.-J., Ding, Z., Yue, Z., Ren, H., Jiang, Y., & Wang, J. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0823-0 · Cited by 84
“Meanwhile, Gaucher disease, a lysosomal storage disease, is associated with a higher risk of developing PD [6].”
BackgroundGlucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy
De Marco, E. V., Annesi, G., Tarantino, P., Rocca, F. E., Provenzano, G., Civitelli, D., Cirò Candiano, I. C., Annesi, F., Carrideo, S., Condino, F., et al. (2008) · Movement Disorders · doi:10.1002/mds.21892 · Cited by 83
Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease
Пчелина, С. Н., Emelyanov, A., Baydakova, G., Andoskin, P. A., Senkevich, K. A., Nikolaev, M. A., Miliukhina, I. V., Yakimovskii, А. F., Timofeeva, A., Fedotova, E. Y., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.039 · Cited by 87
Chérin, P., Rose, C., de Roux‐Serratrice, C., Tardy, D., Dobbelaere, D., Grosbois, B., Hachulla, E., Jaussaud, R., Javier, R. ‐., Noël, E., et al. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9095-5 · Cited by 78
“Conversely, glucocerebrosidase gene mutations have recently emerged as a potential risk factor for idiopathic PD (Aharon-Peretz et al. 2004; Bembi et al. 2003; Clark et al. 2005; Gan-Or et al. 2008; Machaczka et al. 1999; McKeran et al. 1985; Tayebi et al. 2003; Ziegler et al. 2007).”
BackgroundThe association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism
DePaolo, J., Goker‐Alpan, O., Samaddar, T., Lopez, G., & Sidransky, E. (2009) · Movement Disorders · doi:10.1002/mds.22538 · Cited by 79
“One such clinic-based study in northern Israel screened 99 Ashkenazi patients with classic PD symptoms.(11) DNA samples were tested for several common glucocerebrosidase mutations.”
BackgroundInsights into the structural biology of Gaucher disease
Smith, L., Mullin, S., & Schapira, A. H. V. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.09.010 · Cited by 87
“As both homozygous and heterozygous GBA mutation carriers are associated with risk for PD (Aharon-Peretz et al., 2004), this may suggest that reduced GCase activity is not solely responsible for disease onset.”
BackgroundMechanisms of alpha-synuclein toxicity: An update and outlook
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.10.005 · Cited by 75
The relationship of alpha-synuclein to mitochondrial dynamics and quality control
Thorne, N. J., & Tumbarello, D. A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.947191 · Cited by 82
Wu, G., Wang, X., Feng, X., Zhang, A., Li, J., Gu, K., Huang, J. A., Pang, S., Dong, H., Gao, H., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.04.013 · Cited by 83
Neurotransmission systems in Parkinson’s disease
Moghaddam, H. S., Zare-Shahabadi, A., Rahmani, F., & Rezaei, N. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0068 · Cited by 87
Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration
Osellame, L. D., & Duchen, M. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12453 · Cited by 84
Glucocerebrosidase Mutations and Risk of Parkinson Disease in Chinese Patients
Tan, E., Tong, J., Fook-Chong, S. M. C., Yih, Y., Wong, M. C., Ratnagopal, P., & Zhao, Y. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.1056 · Cited by 77
“Recent observation of an association between Parkinson disease (PD) and GBA gene mutations in Ashkenazi Jewish patients has generated considerable scientific interest.(2) However, data on this association in non–Ashkenazi Jewish populations is still limited.”
BackgroundNeurological evaluation of patients with Gaucher disease diagnosed as type 1
Capablo, J. L., de Cabezón, A. S., Fraile, J., Alfonso, P., Pocoví, M., Giraldo, P., & on behalf of the Spanish Group on Gaucher Disease (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.111518 · Cited by 77
“Several lines of evidence associate GD and the development of parkinsonism.”
BackgroundMutations in the glucocerebrosidase gene and Parkinson disease: Phenotype–genotype correlation
Aharon-Peretz, J., Badarny, S., Rosenbaum, H., & Gershoni-Baruch, R. (2005) · Neurology · doi:10.1212/01.wnl.0000176987.47875.28 · Cited by 75
Self-citationPremotor biomarkers for Parkinson's disease - a promising direction of research
Haas, B. R., Stewart, T. H., & Zhang, J. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-11 · Cited by 81
“PD and PD-like syndromes associated with GBA mutations were first described in 1996 [107], and have subsequently been demonstrated to occur at much higher frequencies in PD patients than controls in pan-ethnic populations from Israel [108,109], Italy [110], China [111,112], North Africa [113], Great Britain [114], Eur…”
BackgroundFukushima, H., Takenouchi, T., & Kosaki, K. (2016) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37829 · Cited by 75
“…polygenic disorders depending on the gene dosage is reminiscent of the relationship that is observed for the GBA (glucocerebrosidase) gene, in which homozygosity leads to Gaucher disease and heterozygosity represents a risk allele for idiopathic Parkinson disease [Aharon-Peretz et al., 2004].”
BackgroundNicoletti, V., Palermo, G., Prete, E. D., Mancuso, M., & Ceravolo, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636506 · Cited by 81
ATP13A2 variants in early‐onset Parkinson's disease patients and controls
Djarmati, A., Hagenah, J., Reetz, K., Winkler, S., Behrens, M. I., Pawlack, H., Lohmann, K., Ramirez, A., Tadić, V., Brüggemann, N., et al. (2009) · Movement Disorders · doi:10.1002/mds.22728 · Cited by 72
“with a phenotype more akin to classical EOPD, as has been suggested by the recent ATP13A2 mutation report or for patients carrying heterozygous mutations in the Glucocerebrosidase gene.(25) Homozygous mutations in the latter gene cause Gaucher’s disease and appear to act as a susceptibility factor for PD in the hetero…”
BackgroundParkinson's disease in a dish – Using stem cells as a molecular tool
Badger, J. L., Llana, O. C., Hartfield, E. M., & Wade‐Martins, R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.035 · Cited by 87
Genetically engineered mouse models of Parkinson's disease
Crabtree, D. M., & Zhang, J. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.07.019 · Cited by 70
“[3 9] Tr em or , r ig id it y”
BackgroundInfluentialNew therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Senkevich, K. A., Rudakou, U., & Gan‐Or, Z. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108822 · Cited by 75
Klein, C., Schneider, S. A., & Lang, A. E. (2009) · Movement Disorders · doi:10.1002/mds.22675 · Cited by 72
“Parkinsonism may also develop in patients with otherwise typical type Gaucher’s disease and two mutated GBA alleles.(114,115)”
BackgroundThe contribution of mutantGBAto the development of Parkinson disease inDrosophila
Maor, G., Cabasso, O., Krivoruk, O., Rodriguez, J., Steller, H., Segal, D., & Horowitz, M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw129 · Cited by 88
High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews
Shiner, T., Mirelman, A., Gana Weisz, M., Bar-Shira, A., Ash, E., Cialic, R., Nevler, N., Gurevich, T., Bregman, N., Orr-Urtreger, A., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1593 · Cited by 69
The Genetic Basis of Phenotypic Heterogeneity in the Neuronal Ceroid Lipofuscinoses
Gardner, E., & Mole, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.754045 · Cited by 77
“This has been described for other rare diseases and more common neurological disorders, such as Niemann-Pick C disease with Alzheimer’s disease (37), and type 1 Gaucher disease with Parkinson’s disease (38).”
BackgroundUbiquitin–proteasome system dysfunction in Parkinson’s disease: current evidence and controversies
Lim, K.-L. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.6.769 · Cited by 71
Gaucher disease and parkinsonism
Sidransky, E. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.11.007 · Cited by 72
Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations
Choi, J. H., Stubblefield, B., Cookson, M. R., Goldin, E., Velayati, A., Tayebi, N., & Sidransky, E. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.008 · Cited by 70
Glucocerebrosidase mutations are also found in subjects with early‐onset parkinsonism from Venezuela
Eblan, M. J., Nguyen, J., Ziegler, S. G., Lwin, A., Hanson, M., Gallardo, M., Weiser, R., Lucca, M. D., Singleton, A., & Sidransky, E. (2005) · Movement Disorders · doi:10.1002/mds.20766 · Cited by 71
Camargos, S., de Oliveira, L. D., Momeni, P., Lees, A. J., Hardy, J., Singleton, A., & Cardoso, F. (2009) · Movement Disorders · doi:10.1002/mds.22365 · Cited by 70
Cognitive impairment and dementia in patients with Parkinson disease.
Leverenz, J. B., Quinn, J. F., Zabetian, C. P., Zhang, J., Montine, K. S., & Montine, T. J. (2009) · PubMed · Cited by 93
Gallego, C. J., Burt, A., Sundaresan, A. S., Ye, Z., Shaw, C., Crosslin, D. R., Crane, P. K., Fullerton, S. M., Hansen, K., Carrell, D., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.08.008 · Cited by 77
Creese, B., Bell, E., Johar, I., Francis, P. T., Ballard, C. G., & Aarsland, D. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32549 · Cited by 71
Horowitz, M., Braunstein, H., Zimran, A., Revel‐Vilk, S., & Göker-Alpan, Ö. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114402 · Cited by 73
Smith, L. J., Lee, C., Menozzi, E., & Schapira, A. H. V. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.971252 · Cited by 71
“Biallelic or monoallelic variants in the GBA1 gene are found in 10-15% of PD cases worldwide, and up to 30% of cases of Ashkenazi Jewish (AJ) ancestry (25).”
Background
Metadata
- Authors
- Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Rosenbaum, Hanna
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-04
- Volume
- 351
- Issue
- 19
- Pages
- 1972-1977
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992253341
- Cited by
- 597
- References
- 32
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 17 · 2023: 21 · 2022: 32 · 2021: 27 · 2020: 16 · 2019: 25 · 2018: 26 · 2017: 32 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 39 · 2012: 28
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase gene, GBA mutations, Ashkenazi Jews, N370S mutation, Alzheimer's disease, parkinsonism, genetic screening, heterozygosity, genotype-phenotype correlation, gene-environment interaction
- MeSH terms
- Alzheimer Disease, DNA Mutational Analysis, Female, Glucosylceramidase, Heterozygote, Humans, Jews, Male, Mutation, Parkinson Disease, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.